Research Articles >
College of Health Sciences >
Please use this identifier to cite or link to this item:
|Title: ||Long-term responses to first-line antiretroviral therapy in HIV and hepatitis B co-infection in Ghana|
|Authors: ||Sarfo, Fred Stephen|
Geretti, Anna Maria
Chadwick, David R.
|Keywords: ||Hepatitis B|
|Issue Date: ||2014|
|Publisher: ||Journal of infection|
|Citation: ||Journal of Infection, (2014) 69, 481-489|
|Abstract: ||Summary Objectives: To observe the long term response to first-line antiretroviral therapy
(ART) in HIV and hepatitis B virus (HBV) co-infected patients in Ghana and explore predictors
of poor clinical outcomes.
Methods: Retrospective cohort study of hepatitis B surface antigen (HBsAg) positive and negative
patients receiving predominantly NNRTI-based ART with lamivudine plus either zidovudine
or stavudine for up to seven years. Cox proportional hazards and Kaplan Meier survival analyses
compared clinical outcomes and identified baseline characteristics predictive of poor outcomes.
A mixed effects model compared changes in CD4 counts.
Results: A total of 299 HBsAg-positive and 1869 HBsAg-negative patients started ART between
2004 and 2008. Over a median 35 months of follow-up, HBsAg-positive patients were more
likely to die or default care than HBsAg-negative patients, aHR 1.36 (95% CI, 1.03e1.80).
HBsAg-positive patients were also more likely to develop Grade 3/4 hepatotoxicity than
HBsAg-negative patients, HR 1.99 (1.16e3.40) on survival analysis. There was no significant difference
in CD4 responses between HBsAg-positive and HBsAg-negative patients.|
|Description: ||An article published in Journal of Infection, (2014) 69, 481-489|
|Appears in Collections:||College of Health Sciences|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.